Date: 2017-04-17

Type of information: Establishment of a new subsidiary in the US

Compound: MANF Therapeutics (USA – CA)

Company: Amarantus BioScience (USA – CA) MANF Therapeutics (USA – CA)

Therapeutic area: Ophtalmological diseases - Neurodegenerative diseases

Type agreement: establishment of a new subsidiary in the US

Action mechanism:

Disease: retinitis pigmentosa, retinal artery occlusion, glaucoma, Parkinson's disease


  • • On April 17, 2017, Amarantus Bioscience , a US-headquartered biotechnology company focused on developing products for regenerative medicine, neurology and orphan diseases, announced that it has formed a wholly-owned subsidiary named MANF Therapeutics, for the purpose of the continued pre-clinical development of the internally discovered MANF program in development for the treatment of ophthalmological disorders, including the orphan indications retinitis pigmentosa and retinal artery occlusion, in addition to glaucoma and Parkinson's disease. Amarantus' PhenoGuard protein discovery engine that led to MANF's discovery will also be an asset of MANF Therapeutics.
  • MANF (mesencephalic-astrocyte-derived neurotrophic factor) has completed safety and efficacy animal proof of concept studies in retinitis pigmentosa, retinal artery occlusion, glaucoma and Parkinson's diseasee. Going forward MANF Therapeutics will be focused on the most attractive source of funding to complete cGMP manufacturing for human grade MANF to initiate clinical trials, as well as other IND-enabling studies.
  • ¤ Retinitis pigmentosa: MANF has demonstrated positive pre-clinical data in a number of models of retinitis pigmentosa including, a chronic degenerative genetic disorder. The data demonstrates that MANF has the ability to protect rods and cones, as well as improve visual acuity via improvement in cellular electrical signaling. MANF has demonstrated the ability to protect rods, cones and retinal ganglion cells in acute injury models, including ischemia/reperfusion models, consistent with data in other ischemia-related indications (such as cardiovascular ischemia and cerebral ischemia).
  • ¤ Parkinson's disease: MANF has demonstrated the ability to protect and restore the function of dopaminergic neurons in various models of Parkinson's disease, as well as the ability to deliver the drug appropriately to the right location of the brain using Convection Enhanced Delivery.

Financial terms:

Latest news:

Is general: Yes